The pharmaceutical company AstraZeneca announced today that its vaccine against Covid-19, Vaxzevria, has been approved by the European Union regulator (Coreper) as the third boost.
The vaccine can now be used as a booster after two doses of Vaxzevria or from people who have previously been vaccinated with an mRNA vaccine, such as the Pfizer / BioNTech and Moderna vaccines.
“Ensuring longer-lasting immunoprotection is key to the long-term management of Covid-19 as a whole, and booster doses can counteract the weakening of protection over time that has been identified with all basic vaccination regimens to date,” he said in a statement. Mene Pangalos, Executive Vice President of Biopharmaceutical Research and Development at AstraZeneca.
The European Medicines Agency has approved the use of Vaxzevria as a booster dose a few weeks after the European regulator approved the use of the Pfizer-BioNTech Comirnaty vaccine as a booster dose for adults who have completed the basic vaccine regimen.
Vaccine pharmaceutical companies have announced that the largest volume of vaccines this year will be booster doses or the basic vaccination regimen for children as it receives worldwide approval.
The decision of the European regulatory authority must be formally ratified by the European Commission.
SOURCE: AMPE
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
